Never give up on us: Virat Kohli's plea to fans

New Delhi, Jan 11: Senior Congress leader P Chidambaram on Friday said that he has never seen innocents like the Indian people, who believe the claims made by the government on the implementation of its programmes. The former Union Minister, addressing a literary event, said, "I have never seen innocents like the Indian people. If something appears on print (and named two newspapers also), we believe it. We believe anything."

Claims like all villages having been electrified in the country and toilets built for 99 per cent of families in India were being believed, he said.

Similar was the case of the Ayushman Bharat scheme, (Pradhan Mantri Jan Arogya Yojana or PM-JAY is a flagship health care scheme of the Centre), he alleged.

Stating that his Delhi-based driver's father had to get a surgery done under the scheme, he said, however, it could not be performed.

"I asked him (car driver) if he had the Ayushman card and he showed a card and I told him to take it (to hospital). In hospital after hospital, they said they were not aware of anything like that (Ayushman scheme). But we believe that the Ayushman scheme has come to the whole of India," he said.

Further, he said "we believe that for any disease, treatment will be done (indicating the Ayushman scheme) without shelling out money. We are being innocents."

Many news items and data were contrary to the truth, he added.

Auckland, Jan 27: : K.L. Rahul made an unbeaten 57 Sunday to steer India to a seven-wicket win over New Zealand in the second Twenty20 international and to a 2-0 lead in the five-match series.

Rahul and Shreyas Iyer put on 86 for the third wicket as India cruised past New Zealand's total of 132-5 with 2.3 overs to spare. Shivam Dube (13 not out) hit a six from the bowling of Tim Southeein in the 18th over to lift India to 135-3.

Iyer made 58 not out and Rahul 56 as India beat New Zealand by six wickets with an over to spare in the first match of the series.

New Zealand made 203-5 batting first in that match but on Sunday, on the same pitch, it struggled to achieve any real momentum. During the second match the pitch played much slower and India bowled expertly to restrict New Zealand's total.

Martin Guptill made 33 in a 48-run opening partnership with Colin Munro and Tim Seifert made an unbeaten 33 at the end of the innings but New Zealand wasn't able to reach a total that could stretch India's deep batting lineup.

Rohit Sharma (8) and captain Virat Kohli (11) were out relatively cheaply but Rahul and Iyer (44) sped India towards a comprehensive victory.

Dube came to the crease shortly before the end and quickly brought the match to a conclusion.

"I think we backed up the first match with a very good performance today, especially with the ball," Kohli said. "We demanded that the bowlers stood up and took control of what we wanted to do out there.

"I think our line and length and the way we wanted to bowl on that wicket, sticking to one side of the wicket and being shorter was a very good feature of us as a team and helped us restrict a very good New Zealand team."

New Zealand's total was inadequate, even on a slower pitch, and India almost toyed with the home side as it made its way to a comfortable win.

New Zealand named the same team that lost the first match of the series and batted after winning the toss, just as it batted when it was outplayed in the first match of the series.

The match raised further questions about the coaching and captaincy of the New Zealand team after its humiliating test series loss in Australia last month. New Zealand showed again Sunday it hasn't the talent to compete with the best teams in the world.

"As a batting unit we probably needed another 15 or 20 to make that total more competitive," said New Zealand captain Kane Williamson. "But credit to the way the India side bowled, they're a class side in all departments and they put us under pressure throughout that middle period."

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.